To determine the anticipated participation in a prophylactic AIDS vaccine trial and to identify perceived benefits and barriers to enrollment of HIV-seronegative volunteers at risk of HIV infection in northern Thailand.
A cross-sectional survey.
Subjects interviewed in a cross-sectional survey included female commercial sex workers (n=215), men attending sexually transmitted disease clinics (n=219), conscripts in the Royal Thai Army (n=1453), and men discharged from the army (n=293) who had returned to civilian life.
Awareness of vaccines (88-97%) and AIDS vaccine development efforts (62-77%) were common and viewed to be a complement to behavior change (74-94%). Approximately 25% of subjects would definitely join a trial if asked, and an additional 38% would accept an AIDS vaccine if they were convinced it would be safe and effective.
Important barriers to participation included concerns with discrimination (16-45%), short- (37-60%) and long-term (30-55%) vaccine side-effects, fear of disability and death (36-58%), and beliefs that partners would refuse to have sex (24-49%) after immunization.
The principal inducement to join a trial was health insurance (62%). Conclusion : Potential HIV vaccine trial participants have several fears of joining a vaccine study at this time.
Information derived from Phase I/II trials is needed to address these concerns if enrollment in efficacy trials is to be successful in the near future.
Mots-clés Pascal : SIDA, Virose, Infection, Volontaire, Homme, Vaccination, Prospective, Essai clinique, Immunoprophylaxie, Vaccin, Facteur risque, Thaïlande, Asie, Attitude, Immunopathologie, Immunodéficit, Prévention
Mots-clés Pascal anglais : AIDS, Viral disease, Infection, Volunteer, Human, Vaccination, Prospective, Clinical trial, Immunoprophylaxis, Vaccine, Risk factor, Thailand, Asia, Attitude, Immunopathology, Immune deficiency, Prevention
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 95-0543134
Code Inist : 002B06D01. Création : 01/03/1996.